Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

Yannan J Wang; Heather R Williams; Bogna N Brzezinska; Anna Gaidis; Bhavi Patel; Janet Munroe; Joseph White; Bunja Rungruang

doi:10.1016/j.gore.2021.100701

Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature

Gynecol Oncol Rep. 2021 Jan 13:35:100701. doi: 10.1016/j.gore.2021.100701. eCollection 2021 Feb.

Authors

Yannan J Wang¹, Heather R Williams², Bogna N Brzezinska², Anna Gaidis², Bhavi Patel³, Janet Munroe³, Joseph White⁴, Bunja Rungruang²

Affiliations

¹ Medical College of Georgia at Augusta University, 1120 15th St., Augusta, GA 30912, Georgia.
² Division of Gynecologic Oncology, Augusta University, Medical College of Georgia, 1120 15th St., Augusta, GA 30912, Georgia.
³ Division of Radiology, Augusta University, Medical College of Georgia, 1120 15th St., Augusta, GA 30912, Georgia.
⁴ Division of Pathology, Augusta University, Medical College of Georgia, 1120 15th St., Augusta, GA 30912, Georgia.

Abstract

•Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate.•Microsatellite instability (MSI)-high ULMS is not well documented in current literature.•Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high solid tumors.•Targeting MSI-high ULMS with pembrolizumab can potentially maintain a patient's quality of life and extend overall survival.

Keywords: Immune checkpoint inhibitors; Microsatellite instability; Pembrolizumab; Uterine leiomyosarcoma.

Publication types

Case Reports